These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Non-alcoholic fatty liver disease: Definition and subtypes. Han SK; Baik SK; Kim MY Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427 [TBL] [Abstract][Full Text] [Related]
6. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Oda K; Uto H; Mawatari S; Ido A Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848 [TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver disease; a full-bodied epidemic]. Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638 [TBL] [Abstract][Full Text] [Related]
9. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Marengo A; Rosso C; Bugianesi E Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416 [TBL] [Abstract][Full Text] [Related]
10. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Kanneganti M; Singal AG Gastroenterology; 2022 May; 162(6):1772-1774. PubMed ID: 35120916 [No Abstract] [Full Text] [Related]
11. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631 [TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
14. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Cernea S; Onișor D World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124 [TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Dhamija E; Paul SB; Kedia S Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369 [TBL] [Abstract][Full Text] [Related]
16. Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease. Long J; Bian J; Zhao H J Hepatol; 2021 Jun; 74(6):1493-1494. PubMed ID: 33476746 [No Abstract] [Full Text] [Related]
17. Clinical features and management issues of NAFLD-related HCC: what we know so far. Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057 [TBL] [Abstract][Full Text] [Related]
18. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812 [TBL] [Abstract][Full Text] [Related]
19. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Younossi ZM; Harring M; Younossi Y; Ong JP; Alqahtani SA; Stepanova M Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2915-2917.e1. PubMed ID: 34666156 [TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]